Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Leon Berard
With
Ministry of Health, France
C. R. Bard
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women older than 18 years old;
Breast cancer diagnosis histologically proven , for any histological subtypes;
4 or 6 indication of neoadjuvant or adjuvant chemotherapy; according to hormonal status and HER2 of the tumors, the patient may be treated concomitantly with hormone therapy and / or trastuzumab; Nota Bene: treatment protocol adopted will imperatively be administered in 3-week cycles.
Central venous access indication;
Ability to understand and willingness to comply with the study monitoring;
Affiliated to the French social security system;
Informed Consent dated and signed, indicating that the patient has been informed of all pertinent aspects of the study before inclusion.
You may not be if
Any contraindication for placement of a central venous catheter ( hemostasis disorders , active infection treated with antibiotics , ...);
Patient who can't stop anti -vitamin K treatment ( AVK ) ( a relay by Heparin Low Molecular Weight (LMWH) is possible);
History of central access, regardless of the indication;
Any active disease other than cancer pathology , requiring repeated administration of intravenous therapy ;
Patient deprived of liberty;
Not monitoring for social, geographical, psychological or family reason.
Clareo Health | Iterative PICC Placement Versus Long Term Device
